Roivant
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Anika Sharma
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Sanofi Joins Forces with Teva, Merck, and Roivant in $500M Deal for Bowel Disease Race
Anika Sharma
Sanofi is making significant financial moves in the pharmaceutical landscape. Just one day after sealing a $175 million vaccine deal, ...
Roivantās IMVT-1402 lowers IgG without cholesterol or albumin issues, boosting CEO Glineās debut
Anika Sharma
Roivant CEO Matt Gline faced an immediate challenge in 2021 when he took the helm, discovering that Immunovant’s lead asset ...
